Table 1.

FDA- and EMA-approved nanomedicines since 2015, updated from Sainz et al. [13]

Tradename	Nanoplatform and active agent	Application	Approval (date)	Company
Adynovate®/Adynovi®	PEGylated recombinant anti-hemophilic factor	Hemophilia	FDA (2015) EMA (2017)	Takeda
Aristada®	Aripiprazole lauroxil nanocrystals	Schizophrenia	FDA (2015)	Alkermes
Glatopa® (Generic of Copaxone)	Random copolymer of L-glutamate, L-alanine, L-lysine, and L-tyrosine	Multiple sclerosis	FDA (2015)	Novartis
Invega Trinza®/Trevicta®	Paliperidone palmitate nanocrystals	Schizophrenia	FDA (2015) EMA (2016)	Janssen
Inveltys®	Loteprednol etabonate nanosuspension	Post-operative ophthalmic inflammation	FDA (2018)	KALA pharmaceuticals
Mircera®	PEGylated epoetin beta	Anemia in chronic renal diseases for pediatric patients	FDA (2018) EMA (2019)	Vifor
mRNA-1273	Lipid nanoparticle of full-length, prefusion stabilized spike protein mRNA	Prevention of COVID-19	FDA (2020) EMA (2021)	Moderna
Onpattro® (Patisiran)	Lipid nanoparticle for siRNA targeting TTR protein	TTR-mediated amyloidosis	FDA and EMA (2018)	Alnylam Pharmaceuticals
Onivyde®	PEGylated liposomal irinotecan	Metastatic pancreatic cancer	FDA (2015) EMA (2016)	Merrimack
Rebinyn®/Refixia®	PEGylated glyco-protein drug	Hemophilia	FDA and EMA (2017)	NovoNordisk
Sublocade®	Buprenorphine-loaded PLGA nanoparticles	Opioid use disorder	FDA (2017)	Indivior
Tozinameran®	Lipid nanoparticle of full spike mRNA	Prevention of COVID-19	FDA and EMA (2020)	BioNTech SE and Pfizer
Vyxeos®	Liposomal formulation of cytarabine: daunorubicin (5:1 M ratio)	Acute myeloid leukemia	FDA (2017) EMA (2018)	Jazz Pharmaceuticals
Zilretta®	PLGA hydrogel of triamcinolone acetonide	Knee osteoarthritis	FDA (2017)	Flexion Therapeutics

FDA Food and Drugs Administration, EMA European Medicines Agency, TTR transthyretin, PLGA poly(lactic-co-glycolic acid), PEG polyethylene glycol, COVID-19 coronavirus disease 2019